Anti-Tumour Efficacy Study Of The Bruton’s Tyrosine Kinase (Btk) Inhibitor, ONO-4059, In Combination With The Glycoengineered Type II Anti-CD20 Monoclonal Antibody, Obinutuzumab (GA101) Demonstrates Superior In Vivo Efficacy Compared To ONO-4059 In Combination With Rituximab
Toshio Yoshizawa, Tomoko Yasuhiro, Joseph TP Birkett et al.
Key Points:
Btk inhibitor ONO-4059 combining with anti-CD20 Abs, Obinutuzumab (GA101) or Rituximab (RTX).
Novel therapeutic strategy in ABC-DLBCL and CLL as well as other B-cell malignancies.
In vitro with TMD-8 xenograft model using TMD-8 tumor cells, a human ABC-DLBCL cell line.
Tumor remission seen with combination treatment with GA101 in 3/10 animals.
Implications:
- Combination treatment with ONO-4059 with GA101 or rituximab results in combined effect superior to respective monotherapies.
View the original abstract on the ASH website.
